KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today ...
(RTTNews) - Viatris (VTRS) announced the launch in Canada of Gen-Clozapine orally disintegrating tablets, providing a new treatment option for treatment-resistant schizophrenia patients. This marks ...
- DARTISLA ODT is available as a 1.7 mg orally disintegrating tablet and is indicated for adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer PARSIPPANY, ...
SOMERSET, N.J., Mar. 7, 2019 /PRNewswire-PRWeb/ -- Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer ...
Please provide your email address to receive an email when new articles are posted on . MindMed will use Catalent’s Zydis orally disintegrating tablet technology for the development of MM-120, an ...
Endo, Inc (OTCQX: NDOI) (“Endo”), announced today that one of its operating subsidiaries, Endo USA, Inc., is voluntarily recalling one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.25 ...
ORLANDO -- An orally disintegrating tablet form of sebetralstat (Ekterly) for young children with hereditary angioedema (HAE) showed similar results as the non-disintegrating tablet used in adults, a ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results